<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737359</url>
  </required_header>
  <id_info>
    <org_study_id>RFSP-AMDX-2010</org_study_id>
    <nct_id>NCT01737359</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.</brief_title>
  <official_title>A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RFS Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RFS Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind Phase 2a study to test the safety and efficacy of an investigational
      HIV drug, amdoxovir (300 mg or 500 mg twice daily) compared with tenofovir DF 300 mg once
      daily in HIV-1 infected antiretroviral therapy-experienced subjects who are currently failing
      antiretroviral therapy. There are three treatment groups (N=45). Subjects will be randomized
      to receive either amdoxovir 300 mg twice daily (n=15) or amdoxovir 500 mg twice daily (n=15)
      or tenofovir DF 300 mg once daily (n=15); each in combination with zidovudine 300 mg twice
      daily.

      The study will assess initially amdoxovir (300 mg or 500 mg twice daily) or tenofovir DF 300
      mg once daily, both in combination zidovudine 300 mg twice daily plus failing third drug, but
      then with lopinavir/ritonavir (400 mg/100 mg twice daily) after Week 2. Subjects who received
      amdoxovir (300 mg or 500 mg twice daily) and benefited from the drug may choose to enroll in
      the 36-week open-label study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 viral load</measure>
    <time_frame>change from baseline to Week 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability- Incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>number and frequency from baseline through Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 viral load</measure>
    <time_frame>change from baseline to Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Immunologic Function (CD4 cell counts)</measure>
    <time_frame>changes from baseline to Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Human Immunodeficiency Virus Infection</condition>
  <arm_group>
    <arm_group_label>amdoxovir 300 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amdoxovir 500 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tenofovir DF 300 mg qd</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amdoxovir 300 mg bid</intervention_name>
    <description>2 x 150 mg capsules bid</description>
    <arm_group_label>amdoxovir 300 mg bid</arm_group_label>
    <other_name>DAPD</other_name>
    <other_name>AMDX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amdoxovir 500 mg bid</intervention_name>
    <description>2 x 250 mg capsules bid</description>
    <arm_group_label>amdoxovir 500 mg bid</arm_group_label>
    <other_name>DAPD</other_name>
    <other_name>AMDX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir DF 300 mg qd</intervention_name>
    <description>1 x 300 mg tablet once daily</description>
    <arm_group_label>tenofovir DF 300 mg qd</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years old with HIV-1 RNA ≥ 2,000 copies/mL and currently failing
             therapy.

          -  Has M184I/V mutation in addition to 0-2 thymidine analog mutations (TAMs) at
             screening.

          -  Agree to be abstinent or use two reliable forms of contraception (for females) and one
             form for men when participating in sexual activity that could result in pregnancy.

        Exclusion Criteria:

          -  Current or recent (last 30 days of study entry) AIDS defining diseases.

          -  Genotypic resistance testing at screening indicating K65R, L74V, Q151M mutation.

          -  Prior exposure to lopinavir/ritonavir or amdoxovir.

          -  Impaired hepatic function (ALT &gt; 5 x ULN).

          -  Women who are pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luz Pascual, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>RFS Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CXP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1141ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405CKC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426EGR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amdoxovir</keyword>
  <keyword>zidovudine</keyword>
  <keyword>tenofovir DF</keyword>
  <keyword>HIV</keyword>
  <keyword>HAART</keyword>
  <keyword>antiretroviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

